Micro-Dystrophin Domain Selection for Cardiac Arrhythmia Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Duchenne muscular dystrophy, particularly cardiac arrhythmias, lack an effective composition and method to address the specific needs of cardiac muscle protection, as dystrophin domains important for skeletal muscle protection may not necessarily be important for heart protection.
Innovation Solution
A composition comprising a micro-dystrophin with specific domains (N-terminal, R16, R17, R18, R19, and CR domains) is administered using viral vectors, particularly adeno-associated viral vectors, to provide cardiac protection and treat cardiac arrhythmias in subjects with Duchenne muscular dystrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If full-length dystrophin is used for skeletal muscle protection, then skeletal muscle strength is improved, but cardiac protection is insufficient due to domain mismatch
Solution Approach 1:
The dystrophin protein is segmented into specific functional domains (N-terminal, R16, R17, R18, R19, and CR domains) that are critical for cardiac protection. This segmented approach allows selection and expression of only the cardiac-protective domains rather than the full-length protein, resolving the domain mismatch issue between skeletal and cardiac muscle protection.
Solution Approach 2:
Different domains of dystrophin are assigned different functional qualities based on tissue-specific requirements. The micro-dystrophin construct provides localized cardiac protection by expressing only the domains (N-terminal, R16-R19, CR) that are specifically important for heart function, while skeletal muscle protection domains are excluded.
2Reliability
If micro-dystrophin with specific domains is administered, then cardiac protection is improved, but treatment complexity increases due to viral vector requirements
Solution Approach 1:
The micro-dystrophin construct serves multiple functions simultaneously: it protects cardiac muscle, rescues impaired sodium currents in Purkinje fibers, and prevents cardiac arrhythmias. This multi-functionality is achieved through a single viral vector administration, which simplifies the overall treatment approach despite the complexity of the molecular construct.
3Productivity
If viral vectors are used to deliver micro-dystrophin, then delivery efficiency is improved, but safety concerns arise from viral administration
Solution Approach 1:
Viral vectors serve as intermediary carriers to deliver the micro-dystrophin gene to cardiac tissue. This intermediary approach enables efficient gene delivery without requiring direct administration of the protein itself, allowing for sustained expression while maintaining controlled viral vector selection to minimize safety risks.
Data Source
AI summary
Disclosed are compositions and methods for treating Duchenne muscular dystrophy. The compositions include a micro-dystrophin having a dystrophin N-terminal domain, a dystrophin R16 domain, a dystrophin R17 domain, a dystrophin R18 domain, a dystrophin R19 domain, and a dystrophin CR domain. The compositions are particularly useful for treating Duchenne muscular dystrophy and for treating cardiac arrhythmia in subjects having or suspected of having Duchenne muscular dystrophy.